MRSN · As filed with the SEC
Mersana Therapeutics balance sheet, by quarter
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD thousands
| USD thousands | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 56,391 | 76,972 | 102,287 | 107,750 | 78,868 | 58,998 | 75,186 | 174,561 |
| Short-term marketable securities | 0 | 0 | 0 | 26,870 | 76,303 | 103,744 | 107,960 | 34,523 |
| Accounts receivable | 168 | 266 | — | — | 1,000 | 1,570 | — | 0 |
| Prepaid expenses and other current assets | 3,429 | 2,903 | 3,901 | 2,284 | 4,386 | 4,651 | 4,392 | 4,973 |
| Total current assets | 59,988 | 80,141 | 106,188 | 136,904 | 160,557 | 168,963 | 187,538 | 214,057 |
| Property and equipment, net | 163 | 1,037 | 1,887 | 2,203 | 2,603 | 3,005 | 3,408 | 3,831 |
| Operating lease right-of-use assets | 2,035 | 2,895 | 3,739 | 4,578 | 5,392 | 6,182 | 6,949 | 7,694 |
| Other assets, noncurrent | 500 | 500 | 657 | 978 | 978 | 978 | 478 | 478 |
| Total assets | 62,686 | 84,573 | 112,471 | 144,663 | 169,530 | 179,128 | 198,373 | 226,060 |
| Liabilities and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 2,393 | 2,923 | 4,374 | 4,330 | 2,033 | 3,013 | 3,086 | 7,319 |
| Accrued expenses | 14,813 | 15,184 | 12,974 | 18,964 | 18,628 | 17,782 | 15,856 | 21,898 |
| Deferred revenue | 23,770 | 20,183 | 23,715 | 22,168 | 31,372 | 29,345 | 25,618 | 28,147 |
| Operating lease liabilities | 2,293 | 3,270 | 3,961 | 3,856 | 3,753 | 3,654 | 3,547 | 3,252 |
| Short-term debt | — | — | — | — | — | — | — | 2,083 |
| Short-term debt, net | 0 | 17,351 | 12,500 | 12,500 | 11,458 | 8,333 | 5,208 | — |
| Other current liabilities | 0 | 427 | 637 | 640 | 1,057 | 57 | 91 | 938 |
| Total current liabilities | 43,269 | 59,338 | 58,161 | 62,458 | 68,301 | 62,184 | 53,406 | 63,637 |
| Operating lease liabilities, noncurrent | 0 | 0 | 262 | 1,292 | 2,295 | 3,271 | 4,224 | 5,149 |
| Long-term debt, net | — | — | — | — | — | — | 20,098 | — |
| Long-term debt, net | 0 | 0 | 7,901 | 10,950 | 13,999 | 17,049 | — | 23,148 |
| Deferred revenue, noncurrent | 78,954 | 78,381 | 77,015 | 79,464 | 83,865 | 87,571 | 92,022 | 97,167 |
| Other liabilities, noncurrent | 0 | 0 | 0 | 8 | 21 | 626 | 638 | 55 |
| Total liabilities | 122,223 | 137,719 | 143,339 | 154,172 | 168,481 | 170,701 | 170,388 | 189,156 |
| Stockholders' deficit: | ||||||||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 350,000,000 shares authorized; 4,998,500 and 4,626,010 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 0 | 0 | 12 | 12 | 12 | 12 | 12 | 12 |
| Additional paid-in capital | 891,980 | 890,826 | 888,796 | 886,022 | 882,448 | 878,421 | 873,730 | 863,242 |
| Accumulated other comprehensive income | 0 | 0 | 0 | 10 | 25 | (71) | (90) | 11 |
| Accumulated deficit | (951,517) | (943,972) | (919,676) | (895,553) | (881,436) | (869,935) | (845,667) | (826,361) |
| Total stockholders’ deficit | (59,537) | (53,146) | (30,868) | (9,509) | 1,049 | 8,427 | 27,985 | 36,904 |
| Total liabilities and stockholders’ deficit | 62,686 | 84,573 | 112,471 | 144,663 | 169,530 | 179,128 | 198,373 | 226,060 |
| Common stock, shares authorized (in shares) | — | — | — | — | — | — | — | 350,000,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.